Oral Aripiprazole Open-Label Rollover Study

Phase 3

Completed

• Conditions: Schizophrenia
• Interventions: Drug: Aripiprazole

• Registration Number: NCT01001702
• Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Brief Summary

The purpose of this study is to test the long-term safety and tolerability of oral aripiprazole in adolescent patients with schizophrenia.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-04
• Study First Submitted: 2009-10-22
• Study First Submitted QC: 2009-10-23
• Study First Posted: 2009-10-27
• Primary Completion: 2012-07
• Study Completion: 2012-07
• Status Verified: 2013-07
• Results First Submitted: 2013-07-29
• Results First Submitted QC: 2013-07-29
• Last Update Submitted: 2013-07-29
• Results First Posted: 2013-09-27
• Last Update Posted: 2013-09-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 85

Inclusion Criteria

• Subjects with a confirmed Axis I Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnosis of schizophrenia who must have completed Otsuka study 31-03-241 (NCT00102518) treatment of adolescent subjects with schizophrenia

Exclusion Criteria

• Patients with a co-morbid serious, uncontrolled systemic illness
• Patients with a significant risk of committing suicide

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Oral Aripiprazole	Aripiprazole	Flexible dose of oral aripiprazole between 5 mg and 30 mg once daily for 72 months.

Primary Outcome Measures

Name	Time	Method
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuation Due to AEs and Deaths	Up to 72 months	An AE was defined as any new medical problem, or exacerbation of an existing problem, experienced by a subject. Change in clinical relevance (severity increased) was entered as a new AE in the current trial. Abnormal laboratory test findings were considered AEs if, in the opinion of the investigator, they represented an abnormal (clinically significant) change from baseline for that individual subject.; An AE was considered serious if it was fatal; life-threatening; persistently or significantly disabling or incapacitating; required in-patient hospitalization or prolonged hospitalization; a congenital anomaly/birth defect; or other medically significant event that, based upon appropriate medical judgment, may have jeopardized the subject and may have required medical or surgical intervention.; Additional information about Adverse Events can be found in the Adverse Event section.

Secondary Outcome Measures

Name	Time	Method
Number of Participants Experiencing Suicidal Ideation or Suicidal Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS)	Baseline, Up to 72 months	The C-SSRS consisted of a baseline evaluation (completed at the first scheduled visit upon approval of protocol Amendment 3) that assessed the lifetime experience of the participant with suicide events and suicidal ideation and a post-baseline evaluation at each visit that focused on suicidality since the last trial visit. Some questions are yes/no and some are on a scale of 1 (low severity) to 5 (high severity). The number of participants experiencing suicidal ideation or suicidal behavior is reported.
Change From Baseline in Clinical Global Impression Severity of Illness (CGI-S) Score	Baseline, Last Visit (Up to 72 Months)	The rater or investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" Response choices included: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. A negative change from Baseline indicated improvement
Number of Participants With Clinical Significant Laboratory Tests	Baseline, Up to 72 Months	Blood was collected for Fasting clinical laboratory tests (serum chemistry and hematology) at Baseline, Months 12, 24, 36, 48, 60, and 72 and were analyzed at a central laboratory.; Clinically significant values are defined as the following: Bilirubin, total ≥ 2.0 mg/dL. Creatine phosphokinase \> 500 U/L for participants 13-17 years or 3 times the upper limit of normal for participants ≥ 18 years \[Reference Range (0 to 190 IU/L (females) and 0 to 235 IU/L (males)\].; Eosinophils ≥ 10 %. Hematocrit \< 30 % for participants 13-17 years old or ≥ 18 year old participants female ≤ 32 % and a 3 point decrease from baseline or male ≤ 37 % and a 3 point decrease from baseline.; Hemoglobin female ≤ 9.5 g/dL or male ≤ 11.5 g/dL. Prolactin \> 1 times the upper limit of normal \[Reference range: 2 to 18 ng/mL (males) and 3 to 30 ng/mL (females)\].
Number of Participants With Clinically Significant Heart Rate	Baseline, Up to 72 months	Heart rate was measured at Baseline and at each visit supine (lying on the back) and standing. A heart rate increase is an increase of ≥ 15 beats per minute (bpm) compared to Baseline. A heart rate decrease is a decrease of ≥ 15 bpm compared to Baseline.
Number of Participants With Clinically Significant Blood Pressure	Baseline, Up to 72 months	Systolic and Diastolic blood pressure was measured at Baseline and at all visits supine (lying on the back) and standing.; Systolic increase was an increase of ≥ 20 mm Hg compared to Baseline and systolic decrease was a decrease of ≥ 20 mm Hg compared to Baseline.; A diastolic increase was an increase of ≥ 15 mm Hg compared to Baseline and a diastolic decrease was a decrease of ≥ 15 mm Hg compared to Baseline.
Number of Participants With Clinically Abnormal Changes in Electrocardiograms (ECGs) Evaluations	Baseline, Up to 72 months	A 12-lead ECG was recorded at Baseline, Months 6, 12, 24, 36, 48, 60 and 72. Three readings taken 5 minutes were read by a central ECG reading service and averaged.; Clinically significant ECGs were defined as: Sinus Bradycardia: ≤ 50 beats per minute (bpm), decrease of ≥ 15 bpm from Baseline.; Supraventricular premature beat: ≥ 2 per 10 seconds, increase from Baseline. Ventricular premature beat: ≥ 1 per 10 seconds, increase from Baseline. Right bundle branch block: present. Other intraventricular block: QRS ≥ 0.10 seconds for age 13-17 years or QRS ≥ 0.11 seconds for age ≥ 18 years, an increase of ≥ 0.02 seconds from Baseline.; Symmetrical T-wave inversion: present. QTcB (QT interval corrected Bazett's formula), QTcF (QT interval corrected Fridericia's formula), QTcN (QT corrected FDA Neuropharmacology Division formula), QTcE (QT corrected fractional exponent correction method: ≥ 420 msec for age 13-17 years or ≥ 450 msec for age ≥ 18 years, ≥ 10 % increase from Baseline.
Number of Participants Showing Significant Weight Gain or Loss	Baseline, Up to 72 months	Weight was measured at Baseline, Months 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, and 72. A clinically significant weight gain was defined as a ≥ 7 % increase from Baseline. A clinically significant Weight loss was defined as a ≥ 7% decrease from Baseline.

Trial Locations

Locations (1)

Study site; 🇺🇦 Kiev, Ukraine